Ceftriaxone Preserves Glutamate Transporters and Prevents Intermittent Hypoxia-Induced Vulnerability to Brain Excitotoxic Injury

Abstract

Hypoxia alters cellular metabolism and although the effects of sustained hypoxia (SH) have been extensively studied, less is known about chronic intermittent hypoxia (IH), commonly associated with cardiovascular morbidity and stroke. We hypothesize that impaired glutamate homeostasis after chronic IH may underlie vulnerability to stroke-induced excitotoxicity. P16 organotypic hippocampal slices, cultured for 7 days were exposed for 7 days to IH (alternating 2 min 5% O2 - 15 min 21% O2), SH (5% O2) or RA (21% O2), then 3 glutamate challenges. The first and last exposures were intended as a metabolic stimulus (200 µM glutamate, 15 min); the second emulated excitotoxicity (10 mM glutamate, 10 min). GFAP, MAP2, and EAAT1, EAAT2 glutamate transporters expression were assessed after exposure to each hypoxic protocol. Additionally, cell viability was determined at baseline and after each glutamate challenge, in presence or absence of ceftriaxone that increases glutamate transporter expression. GFAP and MAP2 decreased after 7 days IH and SH. Long-term IH but not SH decreased EAAT1 and EAAT2. Excitotoxic glutamate challenge decreased cell viability and the following 200 µM exposure further increased cell death, particularly in IH-exposed slices. Ceftriaxone prevented glutamate transporter decrease and improved cell viability after IH and excitotoxicity. We conclude that IH is more detrimental to cell survival and glutamate homeostasis than SH. These findings suggest that impaired regulation of extracellular glutamate levels is implicated in the increased brain susceptibility to excitotoxic insult after long-term IH.

Ceftriaxone Treatment Preserves Cortical Inhibitory Interneuron Function via Transient Salvage of GLT-1 in a Rat Traumatic Brain Injury Model

“…Ceftriaxone is a promising candidate antiepileptogenic therapy with documented neuroprotective potential (Cui et al 2014;Jagadapillai et al 2014;Zumkehr et al 2015;Krzyzanowska et al 2017;Tikhonova et al 2017). It may help minimize secondary glutamate excitotoxity by virtue of being a potent stimulator of promoting GLT-1 (EAAT2) expression at concentrations that are achievable in rodents at approximately 200 mg/kg IP, and in the human central nervous system at doses commonly used to treat bacterial meningitis (100 mg/kg/day IV; Max: 4 g/24 h) (Rothstein et al 2005;Lee et al 2008;Lewerenz et al 2009).…”

Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?

“…166,181 Ceftriaxone is a safe and commonly used β-lactam antibiotic approved by the FDA, with good BBB permeability and documented neuroprotective potential. [182][183][184][185][186] It is also a potent stimulator of GLT-1 expression at CNS concentrations that are achievable in humans at doses used to treat bacterial meningitis (100 mg/kg/d, maximum dose = 4 g/d). [187][188][189] Ceftriaxone increases EAAT2 expression via the NFκB signaling pathway.…”

Obstructive sleep apnea is associated with low GABA and high glutamate in the insular cortex

“…The high glutamate may reflect damaging excitotoxic processes arising from intermittent hypoxia (Jagadapillai et al, 2014). Only 5 h of intermittent hypoxia simulating OSA effects can lead to cellular death (Pae et al, 2005); thus, similar processes are probably operating in people with OSA.…”